APERI Pharmaceuticals ^Company

APERI Pharmaceuticals is a biotech company that has developed an oral biologics delivery platform with two patents filed and seven years of research and development. Their initial target market is the Rheumatoid arthritis market with an oral formulation of Adalimumab antibody (Humira). Their technology uses a novel permeation enhancer called AP09, which allows macromolecules to diffuse through tight junctions without causing any toxicity. AP09 is a unique, mechanism-based, target selective, trans-mucosal permeation enhancer that offers a high safety index and highly reversible effect.